摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-氯-1-吗啉-1-丁酮 | 69966-83-2

中文名称
4-氯-1-吗啉-1-丁酮
中文别名
——
英文名称
4-chloro-1-(morpholin-4-yl)butan-1-one
英文别名
4-Chloro-1-morpholinobutan-1-one;4-chloro-1-morpholin-4-ylbutan-1-one
4-氯-1-吗啉-1-丁酮化学式
CAS
69966-83-2
化学式
C8H14ClNO2
mdl
MFCD03988559
分子量
191.658
InChiKey
AJRKKVHASMCUJC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    140-143 °C(Press: 3 Torr)
  • 密度:
    1.167±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.875
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934999090

SDS

SDS:18d3eb35987e78634516346452c66200
查看

反应信息

  • 作为反应物:
    描述:
    4-氯-1-吗啉-1-丁酮 生成 8-oxa-5-azoniaspiro[4.5]decan-4-one;chloride
    参考文献:
    名称:
    ISMAILOV, V. M.;AXMEDOV, SH. T.;GULIEV, A. N.;MOSKVA, V. V., XIM. PREVRASHCHENIYA KISLOROD-, AZOTSODERZH. ORGAN. SOEDIN., BAKU, 1984, +
    摘要:
    DOI:
  • 作为产物:
    描述:
    吗啉4-氯丁酰氯三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 4.0h, 以90%的产率得到4-氯-1-吗啉-1-丁酮
    参考文献:
    名称:
    惰性烷基氯的光氧化还原活化与芳香烯烃的还原交叉偶联
    摘要:
    介绍了惰性氯代烷烃与烯烃交叉偶联反应的光氧化还原活化,在温和条件下具有广泛的官能团耐受性。通过结合 UV/Vis 光谱、EPR、自由基钟和氘标记实验,[Ni(Py 2 Ts tacn)] +被认为具有催化活性来激活 Csp 3 -Cl 键,形成自由基,与烯烃。
    DOI:
    10.1002/anie.202114365
点击查看最新优质反应信息

文献信息

  • Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2- a ]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors
    作者:Yan-Hua Fan、Wei Li、Dan-Dan Liu、Meng-Xuan Bai、Hong-Rui Song、Yong-Nan Xu、SangKook Lee、Zhi-Peng Zhou、Jian Wang、Huai-Wei Ding
    DOI:10.1016/j.ejmech.2017.07.074
    日期:2017.10
    series compounds containing hydrophilic group in imidazo[1,2-a]pyridine and quinazolin-4(3H)-one were synthesized and their antiproliferative activities against five cancer cell lines, including HCT-116, SK-HEP-1, MDA-MB-231, SNU638 and A549, were evaluated. Compound 1i with most potent antiproliferative activity was selected for further biological evaluation. PI3K kinase assay showed that 1i has selectivity
    磷脂酰肌醇3-激酶(PI3K)是细胞内信号通路的关键调节剂,被认为是癌症治疗方法开发中的有希望的靶标。在不同的PI3K亚型中,编码PI3Kp110α的PIK3CA基因在大多数人类癌症中经常发生突变并过表达。因此,抑制PI3Kα被认为是治疗癌症的有效方法。在这项研究中,合成了在咪唑并[1,2- a ]吡啶喹唑啉-4(3H)-one中含有亲基的两个系列化合物,它们对包括HCT-116,SK-HEP-5在内的五种癌细胞系具有抗增殖活性。参照图1,评估了MDA-MB-231,SNU638和A549。化合物1i选择具有最强抗增殖活性的化合物进行进一步的生物学评估。PI3K激酶测定法显示1i对PI3Kα具有选择性,与其他同工型不同。蛋白质印迹分析表明1i在降低磷酸化Akt的平上比基于咪唑吡啶PI3Ka抑制剂HS-173更有效。所有这些结果表明1i是有效的PI3Kα抑制剂,可以被视为开发抗癌药物的潜在候选药物。
  • Efficient Synthesis of a 5-HT<sub>2C</sub> Receptor Agonist Precursor
    作者:René Peters、Pius Waldmeier、Agnès Joncour
    DOI:10.1021/op050065s
    日期:2005.7.1
    followed by reduction to the corresponding aniline 13 and subsequent Boc protection. Acylation of the methyl group in 14 via lithiation furnished γ-chloroketone 16, which was subjected to acid promoted indole formation to afford 17. In the final step, NaOH induced hydrolytic cleavage of the Boc protecting group followed by direct intramolecular nucleophilic substitution gave rise to target molecule 2
    描述了针对三环吲哚生物2的短,可缩放的合成方法,所述三环吲哚生物2是5-HT 2C激动剂1的合成的中间体。合成开始于将便宜的4-硝基-3-甲基苯酚(11)进行Williamson醚化,然后还原为相应的苯胺13,然后进行Boc保护。通过化将14中的甲基酰化,得到γ-氯酮16,将其进行酸促进的吲哚形成,得到17。在最后的步骤,加入NaOH引起的Boc保护基,随后直接分子内亲核取代的解裂解产生了目标分子2中的65%以上六个步骤的总产率。
  • [EN] BENZIMIDAZOLONE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY<br/>[FR] COMPOSES DE BENZIMIDAZOLONE A ACTIVITE D'AGONISTES DU RECEPTEUR 5-HT4
    申请人:PFIZER JAPAN INC
    公开号:WO2005021539A1
    公开(公告)日:2005-03-10
    This invention provides a compound of the formula (I) or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
    该发明提供了式(I)的化合物或其药用可接受的盐,以及含有这种化合物的组合物和利用这种化合物制造用于治疗胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征(IBS)、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合征的药物的用途。这些化合物具有5-HT4受体激动活性,因此对于治疗哺乳动物,尤其是人类的胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等疾病是有用的。
  • Method for inhibiting ADP-induced platelet aggregation using
    申请人:The Dow Chemical Company
    公开号:US04134996A1
    公开(公告)日:1979-01-16
    A method for inhibiting blood platelet aggregation in a mammal by administering internally to the mammal an effective amount of a phenylthio(sulfinyl or sulfonyl)alkylamine compound or a pharmaceutically-acceptable salt thereof.
    通过向哺乳动物内部施用苯基(亚砜或砜基)烷胺化合物或其药用盐的有效量,来抑制哺乳动物的血小板聚集的方法。
  • Benzimidazolone compounds having 5-HT4 receptor agonistic activity
    申请人:Katsu Yasuhiro
    公开号:US20050148573A1
    公开(公告)日:2005-07-07
    This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT 4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
    本发明提供了一种式(I)的化合物或其药学上可接受的盐,并且还提供了包含这种化合物的组合物以及使用这种化合物制造治疗胃食管反流病、胃肠道疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征(IBS)、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病和呼吸暂停综合征的药物的用途。这些化合物具有5-HT4受体激动作用,因此对于哺乳动物,特别是人类的治疗胃食管反流病、非溃疡性消化不良、功能性消化不良、肠易激综合征等非常有用。
查看更多